Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Mar / The Battle Against the Brain-Eating Amoeba
Discovery & Development Drug Discovery Research News

The Battle Against the Brain-Eating Amoeba

How can nanoparticles be used to prevent deaths caused by unicellular organisms?

By Maryam Mahdi 03/31/2020 1 min read Quick Read (pre 2022)

Share

Unicellular organisms like Naegleria fowleri are generally harmless. However, the organism is known by another – far more ominous name – “brain eating amoeba.” Although N. fowleri typically eat bacteria, but if introduced into humans via nostrils (usually via contaminated water during swimming, ablution, bathing, nasal irrigation etc.) they can use brains as a food source. Though such incidences are fortunately rare, morbidity and mortality rates associated with diseases caused by amoeba are rising, particularly in developing countries, where people rely on water storage systems that can fall foul to contamination. Now, researchers at the American University of Sharjah, United Arab Emirates, have designed novel compounds which, when combined with silver nanoparticles, show promise in killing the amoeba.

N. fowleri is attracted to the chemicals that neurons produce when communicating with one another, and will travel through the nose and olfactory nerve before reaching the brain, where it  can cause infections like primary amoebic meningoencephalitis (which causes inflammation and destruction of the brain and its linings) and granulomatous amoebic encephalitis (a rare but usually fatal CNS disease).

“Currently available antimicrobials can cause severe systemic side effects, such as nephrotoxicity, as they are administered intravenously. And that’s one of the reasons why the mortality rate for these diseases is more than 95 percent,” explains Ruqaiyyah Siddiqui at the American University of Sharjah.

Siddiqui and her colleagues tested a variety of quinazolinones and their derivatives in vitro as their antiamoebic effects had not previously been tested. They found that these compounds elicited amoebicidal effects against N. fowleri and Balamuthia mandrillaris, another type of protist pathogen that causes brain infection. The novel compounds alone as well as in combination with silver nanoparticles showed potent effects. They also tested the cytopathogenicity and cytotoxicity of the compounds against amoeba-mediated damage of the human keratinocytes, which resulted in the reduced viability of both pathogens. “We have reported in several studies that the conjugation of silver nanoparticles with novel and existing drugs significantly enhances their effects. Through our experimentation, we have synthesized 34 new quinazolinone derivatives that are effective in killing the amoebae,” Siddiqui and Khan added.

Ruqaiyyah Siddiqui and Naveed Ahmed Khan, another researcher from the American University of Sharjah, now plan to commence further animal and human studies to develop a better understanding of the precise molecular pathways the parasites use to cause disease, with a view to seeking new and effective drug targets. 

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. R Siddiqui, “Aryl quinazolinone derivatives as novel therapeutic agents against brain-eating amoebae”, ACS Chem. Neurosci, (2020).

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.